BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8239517)

  • 21. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
    ter Haar E; Day BW
    Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
    Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
    Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
    Kurbel S
    Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
    Swami S; Krishnan AV; Feldman D
    Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
    Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
    Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of estrogen receptor alpha and progesterone receptor in normal human breast epithelium.
    Umekita Y; Souda M; Ohi Y; Rai Y; Sagara Y; Sagara Y; Yoshida H
    In Vivo; 2007; 21(3):535-9. PubMed ID: 17591366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
    Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
    Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relation between grades of histologic differentiation and hormone receptors in breast cancer].
    Nola N; Separović V; Sarcević B; Graf D; Petrinec Z; Matesa N; Kruslin B
    Lijec Vjesn; 1995; 117(5-6):117-20. PubMed ID: 8600322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The regulatory effect of tamoxifen on fibronectin expression in estrogen-dependent MCF-7 breast carcinoma cells.
    Horii Y; Takei H; Koibuchi Y; Horiguchi J; Maemura M; Iino Y; Morishita Y
    Oncol Rep; 2006 May; 15(5):1191-5. PubMed ID: 16596185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
    Lertsanguansinchai P; Chottetanaprasith T; Chatamra K; Sampatanukul P; Wannakrairot P; Rojpornpradit P; Shotelersuk K; Lertbutsayanukul C; Boonjunwetwat D; Vajragupta L
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S193-202. PubMed ID: 12188412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.
    De Marinis L; Mancini A; Izzi D; Bianchi A; Giampietro A; Fusco A; Liberale I; Rossi S; Valle D
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth inhibitory effect of estrogen conjugated drugs against primary cultured breast cancer cells.
    Matsuoka H; Sugimachi K; Tomoda H; Saito T; Seo Y
    Anticancer Res; 1995; 15(4):1289-96. PubMed ID: 7654011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Studies on sensitivity test with clonogenic assay against chemo-endocrine therapy for human breast cancer].
    Hamada Y
    Nihon Geka Gakkai Zasshi; 1985 Apr; 86(4):411-23. PubMed ID: 4000099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of estrogen and antiestrogen on in vitro clonogenic growth of human breast cancers in soft agar.
    Nomura Y; Tashiro H; Hisamatsu K
    J Natl Cancer Inst; 1990 Jul; 82(13):1146-9. PubMed ID: 2359140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.